GE announces first patient dosed with new PET radiopharmaceutical

2021 11 30 16 39 4000 Ge Rsna 2021 400

GE Healthcare announced that the first patient has been dosed in a phase III trial underway in France with a new dopamine transporter PET imaging radiopharmaceutical.

The agent is for evaluation of adult patients with suspected Parkinson's disease, and it was originally developed by French firm Zionexa, which GE's Pharmaceutical Diagnostic business acquired last year.

The company also has plans to test another dopamine transporter agent it has licensed from brain imaging firm LikeMinds in Boston for use with SPECT imaging, it said.

Page 1 of 548
Next Page